Differences

This shows you the differences between two versions of the page.

--- robby_nieuwlaat [2022/06/13 17:40]
liam [Funding]
+++ robby_nieuwlaat [2022/06/14 20:38] (current)
liam [Funding]
@@ Line 36: / Line 36: @@
 Nieuwlaat is a member of the [[OMERACT]]-Adherence group, studying outcomes in [[rheumatology]]. He has co-authored publications funded by a 2018 [[Arthritis Australia]] project grant (major funder), and a private research grant provided by Professor [[Stephen Hall]].((Kelly, A., Tong, A., Tymms, K., March, L., Craig, J. C., De Vera, M., Evans, V., Hassett, G., Toupin-April, K., van den Bemt, B., Teixeira-Pinto, A., Alten, R., Bartlett, S. J., Campbell, W., Dawson, T., Gill, M., Hebing, R., Meara, A., Nieuwlaat, R., & Shaw, Y. (2018). //Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.// Trials, 19(1). https://doi.org/10.1186/s13063-018-2565-z))
+==== Canadian Stroke Prevention Intervention Network ====
+Nieuwlaat is a Principal Investigator for the Knowledge Translation Program at the [[Canadian Stroke Prevention Intervention Network]].((//Robby Nieuwlaat.// (2014). Canadian Stroke Prevention Intervention Network. https://archive.ph/YcMI6))
 ==== INGUIDE ====
@@ Line 48: / Line 52: @@
 Further funding to study arterial fibrillation has come from [[pharmaceutical_companies:AstraZeneca]], the [[Australian Heart Foundation]], [[Austrian Society of Cardiology]], [[Eucomed]], [[French Federation of Cardiology]], [[Hellenic Cardiological Society]], [[Netherlands Heart Foundation]], [[Portuguese Society of Cardiology]], [[Spanish Cardiac Society]], the [[Swedish Heart and Lung Foundation]], and [[pharmaceutical_companies:Sanofi]].((Dudink, E. A. M. P., Erküner, Ö., Berg, J., Nieuwlaat, R., de Vos, C. B., Weijs, B., Capucci, A., Camm, A. J., Breithardt, G., Le Heuzey, J.-Y., Luermans, J. G. L. M., & Crijns, H. J. G. M. (2017). //The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey.// EP Europace, 20(6), 929–934. https://doi.org/10.1093/europace/eux217))
+He is a member of the [[Global Alliance for Chronic Diseases]] (GACD) Hypertension Research Programme, funded by the [[Canadian Institutes of Health Research]] (CIHR), [[Grand Challenges Canada]], [[International Development Research Centre]], [[Canadian Partnership for Stroke Recovery]], [[Australian National Health and Research Council]], [[National Institutes of Health]], [[National Heart, Lung and Blood Institute]], [[National Institute of Neurological Disorders and Stroke]], [[United Kingdom Medical Research Council]], and the [[South African Medical Research Council]].((Riddell, M. A., Edwards, N., Thompson, S. R., Bernabe-Ortiz, A., Praveen, D., Johnson, C., Kengne, A. P., Liu, P., McCready, T., Ng, E., Nieuwlaat, R., Ovbiagele, B., Owolabi, M., Peiris, D., Thrift, A. G., Tobe, S., & Yusoff, K. (2017). //Developing consensus measures for global programs: lessons from the Global Alliance for Chronic Diseases Hypertension research program.// Globalization and Health, 13(1). https://doi.org/10.1186/s12992-017-0242-8))
+Yet further research has been funded by [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Sanofi]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[Eucomed]], [[University of Basel]], and [[Marche Polytechnic University]].((Guerra, F., Brambatti, M., Nieuwlaat, R., Marcucci, M., Dudink, E., Crijns, H. J. G. M., Matassini, M. V., & Capucci, A. (2017). //Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey.// EP Europace, 19(12), 1922–1929. https://doi.org/10.1093/europace/eux205)) ((Allemann, S. S., Nieuwlaat, R., Navarro, T., Haynes, B., Hersberger, K. E., & Arnet, I. (2017). //Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review.// Journal of Clinical Epidemiology, 91, 70–79. https://doi.org/10.1016/j.jclinepi.2017.07.011)) ((Paquette, M., Riou França, L., Teutsch, C., Diener, H.-C., Lu, S., Dubner, S. J., Ma, C. S., Rothman, K. J., Zint, K., Halperin, J. L., Huisman, M. V., Lip, G. Y. H., & Nieuwlaat, R. (2017). //Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation.// Journal of the American College of Cardiology, 70(13), 1573–1583. https://doi.org/10.1016/j.jacc.2017.07.793))
+==== COVID-19 ====
+Nieuwlaat was lead author on a paper discussing [[antimicrobial resistance]] and [[COVID-19]] sponsored by the [[World Health Organization]].((Nieuwlaat, R., Mbuagbaw, L., Mertz, D., Burrows, L., Bowdish, D. M. E., Moja, L., Wright, G. D., & Schünemann, H. J. (2020). //COVID-19 and antimicrobial resistance: parallel and interacting health emergencies.// Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa773))